HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.

Abstract
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may be a mechanism(s) other than the EGFR pathway that mediates the tumoricidal effects. In the current study, we tested the efficacy of TD-19, a novel compound chemically modified from erlotinib, which has more potent apoptotic effects than erlotinib in EGFR wild-type NSCLC cell lines. TD-19 induced significant cell death and apoptosis in H358, H441, H460, and A549 cells, as evidenced by increased caspase-3 activity and cleavage of procaspase-9 and poly (ADP-ribose) polymerase. The apoptotic effect of TD-19 in H460 cells, which were resistant to erlotinib, was associated with downregulation of cancerous inhibitor of protein phosphatase 2A (CIP2A), increased protein phosphatase 2A (PP2A) activity, and decreased AKT phosphorylation, but minimal effects on EGFR phosphorylation. Overexpression of CIP2A partially protected the H460 cells from TD-19-induced apoptosis. Okadaic acid, a known PP2A inhibitor, significantly reduced TD-19-induced apoptosis, while forskolin, which increased PP2A activity, increased the apoptotic effect of TD-19. TD-19 inhibited the growth of H460 xenograft tumors by ∼80%. We conclude that TD-19 exerted tumoricidal effects on NSCLC cells. TD-19 provides proof that the CIP2A pathway may be a novel target for the treatment of EGFR wild-type NSCLC.
AuthorsTing-Ting Chao, Cheng-Yi Wang, Chih-Cheng Lai, Yen-Lin Chen, Yi-Ting Tsai, Pao-Tzu Chen, Hen-I Lin, Yuh-Chin T Huang, Chung-Wai Shiau, Chong-Jen Yu, Kuen-Feng Chen
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 351 Issue 2 Pg. 352-8 (Nov 2014) ISSN: 1521-0103 [Electronic] United States
PMID25187431 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
Chemical References
  • Autoantigens
  • CIP2A protein, human
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Quinazolines
  • Erlotinib Hydrochloride
  • Poly(ADP-ribose) Polymerases
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins c-akt
  • Protein Phosphatase 2
  • Caspase 3
  • Caspase 9
Topics
  • Animals
  • Apoptosis (drug effects)
  • Autoantigens (metabolism)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, metabolism)
  • Caspase 3 (metabolism)
  • Caspase 9 (metabolism)
  • Cell Line, Tumor
  • Down-Regulation (drug effects)
  • ErbB Receptors (metabolism)
  • Erlotinib Hydrochloride
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Lung Neoplasms (drug therapy, metabolism)
  • Male
  • Membrane Proteins (metabolism)
  • Mice
  • Mice, Nude
  • Phosphorylation (drug effects)
  • Poly(ADP-ribose) Polymerases (metabolism)
  • Protein Phosphatase 2 (metabolism)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Quinazolines (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: